WO2012105816A2 - Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci - Google Patents

Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci Download PDF

Info

Publication number
WO2012105816A2
WO2012105816A2 PCT/KR2012/000797 KR2012000797W WO2012105816A2 WO 2012105816 A2 WO2012105816 A2 WO 2012105816A2 KR 2012000797 W KR2012000797 W KR 2012000797W WO 2012105816 A2 WO2012105816 A2 WO 2012105816A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
powder
diabetes
abse
var
Prior art date
Application number
PCT/KR2012/000797
Other languages
English (en)
Korean (ko)
Other versions
WO2012105816A3 (fr
Inventor
장동규
김문일
김석무
Original Assignee
주식회사 케이오씨바이오텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 케이오씨바이오텍 filed Critical 주식회사 케이오씨바이오텍
Priority to KR1020137017487A priority Critical patent/KR101910898B1/ko
Publication of WO2012105816A2 publication Critical patent/WO2012105816A2/fr
Publication of WO2012105816A3 publication Critical patent/WO2012105816A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K63/00—Receptacles for live fish, e.g. aquaria; Terraria
    • A01K63/003—Aquaria; Terraria
    • A01K63/006—Accessories for aquaria or terraria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a composition for the prevention and treatment of diabetes mellitus and diabetic complications containing a powder ( Aphicarpaea edgeworthii var. Trisperma ) powder or extract thereof as an active ingredient having a hypoglycemic effect.
  • a powder Aphicarpaea edgeworthii var. Trisperma
  • Trisperma a powder or extract thereof as an active ingredient having a hypoglycemic effect.
  • Diabetes mellitus is a disease in which hyperglycemia occurs because cells in the body cannot use sugar due to decreased insulin secretion or reduced insulin function.
  • hormone imbalance including insulin
  • hyperglycemia due to abnormal physiological metabolic control functions such as carbohydrate-containing protein, lipid and electrolyte metabolism, and if such hyperglycemia persists, blood circulation disorders, retinal damage, nerve cell damage, It causes renal insufficiency and vascular complications and serious chronic complications.
  • cardiovascular diseases such as atherosclerosis, cerebral infarction, cerebral thrombosis, and myocardial infarction is higher in diabetic patients than normal patients (Fuller, J.H., Lancet, 1, pp1373-1376, 1980).
  • Diabetes patients have a high risk of death from coronary artery disease or cerebrovascular disease, which are often caused by hypertension, hyperlipidemia, obesity, etc. (Hu-Beom Bum. The Korean Nutrition Society. Abstract, pp. 15-18, 1984). It has been reported that 67% of type 2 diabetics have one or more types of lipid metabolism (Harris, M.I. Diabetes Care, 23, pp754-758, 2000).
  • Type 2 diabetics have increased lipid metabolism with increased triglyceride and cholesterol levels and decreased HDL-cholesterol (Goldberg, RB Diabetes Care, 4, pp561-572, 1981). (Reaven, JW Am. J. Med., 83, pp 31-40, 1987).
  • Diabetes is defined as a metabolic disorder caused by insulin secretion and a lack of action of insulin secreted by pancreatic cells and involves excessive production of glucose, breakdown of body fat and waste of protein, and abnormal glands of glucagon, resulting in metabolic disruption. causes (Abrams, JJ, Ginsberg, H, et al., Diabetes, 31, pp 903-910, 1982).
  • Diabetes mellitus is characterized by two types.Type 1 diabetes mellitus is caused by a deficiency of insulin, a glucose-regulating hormone in the blood, mainly 10-20. It is called juvenile diabetes because it occurs in younger generations. Type 2 diabetes mellitus occurs mainly after the age of 40 and accounts for most of the diabetic patients in Korea. Unlike type 1, it is called adult-type diabetes and the cause of the disease is not clear yet, but it is known to be caused by genetic factors and environmental factors. As a etiology of type 2 diabetes, both insulin secretion in pancreatic beta cells and defects in insulin action (insulin resistance) in target cells are observed.
  • the most important goal in the treatment of diabetes is to control blood glucose levels as close to normal as possible. After fasting blood sugar control along with fasting blood glucose is important for improving diabetes and preventing and treating complications. There is exercise therapy.
  • Oral hypoglycemic agents currently used in patients with type 1 and type 2 diabetes include alpha-glucosidase inhibitors, sulfonylureas, and biguanides.
  • Sidase inhibitors have a therapeutic effect on diabetes by delaying the digestion and absorption of carbohydrates in the ingested diet, thereby reducing the elevation of postprandial blood sugar and blood insulin.
  • Alpha-glucosidase inhibitors promote the secretion of glucagon-like peptide-1, which promotes insulin secretion and suppresses glucagon secretion, without causing hyperinsulinemia or hypoglycemia.
  • Have advantages Mooradian, AD, Thurman, JE et al., Drugs, 57, pp 19-29, 1999; Baron, AD et al., Diabetes Research and Clinical Practice, 40, ppS54-S55, 1998).
  • Acarbose, Boglibose, and Miglitol are currently used in the clinic, but long-term use of alpha-glycosidase inhibitors may cause abdominal bloating, vomiting, and diarrhea in some patients. Side effects may be indicated and their use may be limited (Hanefeld, M. et al., Journal of Diabetes and its Complications, 12, pp228-237, 1998).
  • Bird bean ( Amphicarpaea edgeworthii var. Trisperma ) is a year-old herb belonging to the Zingiberaceae family, a vine-like plant, 1-2m long, with spread hairs facing down. In Korea, it grows wild in wild fields all over the country and is distributed in China, Japan, and India. New beans are also named " Amphicarpaea bracteata subsp.edgeworthii (Benth.) H. Ohashi", " Amphicarpaea edgeworthii var. Japonica ". Leaves are alternate, long petiole, 3 leaflets, ovate, blossom in June-September, flowers are purple. Fruits mature in August.
  • the present invention is to provide a novel substance excellent in postprandial blood sugar suppressing action without any side effects on the living body.
  • the pharmacological effect of the new soybean powder or its extracts was determined through the blood glucose measurement test using the db / db mouse model, the triglyceride in the serum, the total cholesterol, the blood BUN, the ALT and the AST measurement test.
  • the present invention was completed by confirming that there is an excellent therapeutic effect on diabetes, lipid metabolism improvement, and complications caused by diabetes.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of diabetes mellitus or diabetic complications containing a soybean powder or extract thereof as an active ingredient having an excellent hypoglycemic effect.
  • a pharmaceutical composition for the prevention and treatment of diabetes mellitus or diabetic complications containing a powder ( Aphicarpaea edgeworthii var. Trisperma ) or extract thereof as an active ingredient.
  • the extract may be extracted with water, an organic solvent or a mixed solvent thereof.
  • the diabetic complications include arteriosclerosis, cerebral infarction, cerebral thrombosis, myocardial infarction, hypertension, hyperlipidemia, obesity, and the like.
  • a dietary supplement for the prevention and improvement of diabetes mellitus or diabetic complications which contains a bird bean ( Amphicarpaea edgeworthii var. Trisperma ) powder or an extract thereof as an active ingredient.
  • the health functional food of the present invention may have any form of tablets, capsules, powders, granules, liquids, and pills.
  • a dietary supplement comprising Amphicarpaea edgeworthii var.trisperma powder or extracts thereof which shows the effect of improving blood sugar, improving lipid metabolism and preventing and treating diabetes complications.
  • the food includes food, drink, gum, tea, vitamin complex, or health functional food.
  • the blood glucose measurement test using the db / db mouse model, the triglyceride in serum, total cholesterol, total cholesterol, blood BUN, ALT and AST measurement test using a db / db mouse model, diabetes, lipid It was confirmed that there is an excellent therapeutic effect and an excellent hypoglycemic effect on metabolic improvement and complications caused by diabetes.
  • the composition of the present invention using a soybean powder or an extract thereof as an active ingredient may be usefully used as a pharmaceutical composition and health functional food for the prevention and treatment of diabetes or diabetes complications.
  • Figures are mean ⁇ SEM and numbers with different indications differ from one another at specific time points; statistically significant compared to negative control by T test method) * p ⁇ 0.05, *** p ⁇ 0.001)).
  • Figures are mean ⁇ SEM and numbers with different indications differ from one another at specific time points; statistically significant compared to negative control by T test method) * p ⁇ 0.01)).
  • Figures showing triglyceride levels values are mean ⁇ SEM and values with different indications differ from one another at specific time points; statistically compared with negative control by T test method (* P ⁇ 0.01)).
  • urea nitrogen level values are mean ⁇ SEM and values with different indications differ from one another at specific time points; statistically significant compared to negative control by T test method (* P ⁇ 0.01)).
  • ALT levels values are mean ⁇ SEM and values with different indications differ from one another at specific time points; statistically significant compared to negative control by T test method; (* P ⁇ 0.01).
  • FIG. 7 is a diagram showing the effect on blood AST and ALT levels in db / db mice (Makoto T. et. Al., Pulmonary exposure to diesel exhaust particles enhances fatty change of the liver in obese diabetic mice.INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 19: 17-22, 2007).
  • composition of the present invention contains a soybean ( Amphicarpaea edgeworthii var. Trisperma ) powder or an extract thereof as an active ingredient.
  • soybeans defined in the present invention are plants named by the scientific name " Amphicarpaea edgeworthii var. Trisperma ", or " Amphicarpaea bracteata subsp.edgeworthii (Benth.) H. Ohashi” or “ Amphicarpaea edgeworthii var. Japonica ".
  • the soybeans are edible, flat oval, with hairs along the perimeter, with three seeds inside.
  • “soybean” or “soybean seed” means a seed contained in the soybean fruit.
  • the soybean powder includes both dry powder or powdered powder of soybean seed.
  • the extract is a soybean powder of water, an organic solvent or a mixed solvent extract thereof. More preferably, the extract is an extract extracted with water, an organic solvent or a mixed solvent thereof.
  • the diabetic complications include arteriosclerosis, cerebral infarction, cerebral thrombosis, myocardial infarction, hypertension, hyperlipidemia, obesity, and the like, and particularly include hypertension, hyperlipidemia or obesity.
  • soybean powder of the present invention and its extract will be described in detail.
  • soybean powder of the present invention can be ground in a grinder to obtain the soybean powder of the present invention in a dry state.
  • the soybean powder may be increased at 20 to 120 ° C. for about 1 to 72 hours, and dried according to a conventional drying method in the art to obtain the new bean powder of the present invention in the form of a powder.
  • the soybean powder or the powdered soybean dry powder is lyophilized and pulverized, and then a volume of water or an organic solvent of about 2 to 15 times, preferably about 5 to 10 times the weight of the sample, such as methanol, ethanol,
  • the extract of the present invention can be obtained by extraction with a polar solvent of C 1 to C 4 lower alcohols such as butanol, or a mixed solvent thereof.
  • Extraction may be preferably performed using an extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction at 20 to 120 °C for about 1 to 72 hours with water, preferably after extraction under reduced pressure filtration and concentration
  • an extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction at 20 to 120 °C for about 1 to 72 hours with water, preferably after extraction under reduced pressure filtration and concentration
  • the extract of the present invention can be obtained.
  • the soybean powder or extract thereof of the present invention obtained by the method as described above through the blood glucose measurement experiment using the db / db mouse model, triglyceride in serum, total cholesterol, blood BUN, ALT and AST measurement through The therapeutic effect was confirmed. As a result, it was confirmed that there is an excellent therapeutic effect and excellent hypoglycemic effect on diabetes, lipid metabolism improvement and complications caused by diabetes.
  • the new soybean has been used for a long time as an edible or herbal medicine extracts of the present invention extracted therefrom also have no problems such as toxicity and side effects.
  • the pharmaceutical composition for preventing or treating diabetes mellitus or diabetic complications containing the soybean extract of the present invention comprises the extract in an amount of 0.1 to 50% by weight based on the total weight of the composition.
  • compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • compositions of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in any suitable collection.
  • compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods.
  • Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form preparations may contain at least one excipient such as starch, calcium carbonate, sucrose ( Sucrose) or lactose (Lactose), gelatin, etc. are mixed and formulated.
  • excipients such as starch, calcium carbonate, sucrose ( Sucrose) or lactose (Lactose), gelatin, etc. are mixed and formulated.
  • lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • Whitepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the extract of the present invention is preferably administered at 0.0001 to 10000 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the extract of the present invention can be administered to mammals such as mice, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or Intracerebroventricular injection.
  • the present invention provides a health functional food for preventing or treating diabetes or diabetic complications, which contains a powder of the soybean (Aphicarpaea bracteata subsp.edgeworthii (Benth.) H.Ohashi) having a hypoglycemic effect or an extract thereof as an active ingredient. .
  • Health functional food as defined in the present invention means a food manufactured and processed using raw materials or ingredients having a useful function to the human body, and is substantially a health functional food according to the Act No.6727 of the Health Functional Food Act. It is the same meaning as the definition of.
  • the term "functional" means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on the structure and function of the human body.
  • the dietary supplement for preventing diabetes of the present invention comprises the extract in an amount of 0.01 to 95%, preferably 1 to 80% by weight, based on the total weight of the composition.
  • the present invention provides a dietary supplement added to the food or drink for the purpose of improving the blood sugar, extracts thereof soybean sugar improvement, lipid metabolism and prevention and treatment of diabetic complications.
  • the food to which the soybean powder or extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
  • the amount of the extract in the food or beverage may be added to 0.01 to 100% by weight of the total food weight
  • the health beverage composition may be added to about 0.02 to 50g based on 100ml.
  • the health functional beverage composition of the present invention is not particularly limited in the other components, except for containing the above-mentioned extract as an essential ingredient in the indicated ratio, and contains various flavors or natural carbohydrates, etc. as additional ingredients, like ordinary drinks. can do.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
  • the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • the sample of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the sample of the present invention.
  • Saekong Amphicarpaea bracteata subsp.edgeworthii (Benth.) Seeds of the present invention was used as a pulverized and dried from Gyeongbuk Mungyeong woojidong mixer (hereinafter, "ABSE” referred to), 250 ml of the seed to saekong ABSE 500g dry matter after water was added and boiled for 5 minutes at 95-100 °C, and to obtain a powder (hereinafter referred to as, "B-ABSE”) 720g obtained by crushing with a mixer was used for the experiment.
  • ABSE Gyeongbuk Mungyeong woojidong mixer
  • Banaba leaf extract (Banaba leaf extract , purchased from Wellis Banaba Co., Ltd., Brown tablet) was made into a powder, and then diluted or suspended in physiological saline and administered orally twice (10 AM and 6 PM). .
  • mice Six-week-old male db / db mice (26g, Taconic Farms, Inc.) were used to classify three groups of seven for each antidiabetic group, followed by temperature 22 ⁇ 2 ° C, humidity 55 ⁇ 10%, and 12 hours. Proper hypoglycemic efficacy is confirmed for each sample by measuring body weight and blood glucose at 0, 3, 6, 9, 12, and 15 days after sample administration while maintaining in a SPF (specific pathogen free) environment controlled by intervals of contrast. The concentration was chosen.
  • SPF specific pathogen free
  • Drugs were orally administered to this mouse model, and the same amount of saline was administered to the control group.
  • the experimental group db / db mice were randomly assigned to each of the seven dogs, divided into four groups, one group was a vehicle (saline), the positive control group 100mg / kg, and the experimental group prepared in the above Samples of ABSE 2g / kg and B-ABSE 2g / kg were administered orally 0.4ml at 10 AM and 18 PM, respectively.
  • the breeding conditions of each group were the same as those of the preliminary animal experiments.
  • Body weight and blood glucose at 0, 7, 14, and 21 days were maintained while maintaining in an SPF environment controlled by a temperature of 22 ⁇ 2 ° C, 55 ⁇ 10% humidity, and 12 hours of contrast. Changes were performed using a handheld blood glucose meter (OneTouch TM , Johnson & Johnson, USA) and averaged for each experimental group.
  • liver, kidney, heart, pancreas, and lungs are excised and stored in 10% neutral buffered formalin and part of the organs are stored in RNASol B to perform histopathological observations on major organs.
  • the blood glucose of the control group was increased by more than 70% compared to NC from 342.1 mg / dL at 6 weeks to 582.1 mg / dL at 9 weeks.
  • ABSE was the most suppressed blood glucose change from NC at 6 to 9 weeks of age.
  • the ABSE-administered group showed 360.5 mg / kg of 37.9% blood glucose reduction compared to NC (p ⁇ 0.001).
  • the positive control group, banaba extract and B-ABSE showed 26.2% and 26.4% reductions in blood glucose, respectively (p ⁇ 0.001).
  • the 6-week-old db / db mouse model was orally administered with positive control Banaba extract 100 mg / kg, experimental ABSE 2 g / kg, and B-ABSE 2 g / kg twice daily in the morning and afternoon for three weeks.
  • the blood sugar of the control group NC
  • ABSE was the most suppressed blood glucose change from NC at 6 to 9 weeks of age.
  • the ABSE-administered group showed 360.5 mg / kg of 37.9% blood glucose reduction compared to NC (p ⁇ 0.001).
  • the diet was removed on the day before, blood was drawn on an empty stomach (approximately 12 hours), serum was separated, and the glucose level of NC was 641 mg / dL for glucose change in serum using a serum autometer.
  • the ABSE-treated group showed 427.0 mg / dL of 33.4% significant decrease compared to the NC group (p ⁇ 0.01).
  • the triglyceride (TG) level of NC was 67.0 mg / dL
  • the ABSE-treated group was 37.0 mg / dL among the natural-treated groups, which showed a statistically significant reduction of more than 44.7%. (P ⁇ 0.001).
  • Banaba extract a positive control
  • the B-ABSE group was 55.0 mg / dL, which was slightly reduced to 17.9% compared to the NC group, and there was no statistical significance.
  • the BUN level of NC was 27.1 mg / dL, and the ABSE-administered group was not significantly different from the 29.4 mg / dL B-ABSE-administered group compared to the 29.8 mg / dL NC group.
  • Banaba extract was 36.0 mg / dL, showing a statistically significant increase of 32.8% compared to the NC group (p ⁇ 0.05).
  • the diet was removed the day before the end of the experiment, anesthetized with ethyl ether in an empty stomach (about 12 hours), the blood was drawn from the heart with a 3ml syringe, left at room temperature for 1 hour, and then centrifuged at 3000 rpm for 10 minutes. Serum was separated and the total amount of cholesterol in the serum was measured by a serum autometer, and the results are shown in FIG. 5.
  • the total cholesterol level of NC was 142.0 mg / dL
  • the Banaba extract-treated group was 150.0 mg / dL in the natural product group, 151.0 mg / dL in the ABSE group, and 151.0 mg / d in the B-ABSE group. There was no difference between the experimental groups by dL.
  • the ALT level was 78.0 U / L in the NC
  • the Banaba extract-administered group was 65.5 U / L
  • the ABSE-administered group was 100.0 U / L
  • the B-ABSE-administered group was 108.8 U / L.
  • the positive control Banaba extract administration group showed liver function improvement effect compared to NC.
  • the AST level was 189.4 U / L for NC, 90.1 U / L for the barnabas extract group, 171.9 U / L for the ABSE group, and 193.9 U / L for the B-ABSE group.
  • the administration group showed a significant decrease of 51.9% compared to NC, which is close to the normal liver function level of the mice.
  • the experimental group ABSE group and B-ABSE group did not differ from NC.
  • the db / db mouse model is considered to be the reason why the AST level is higher than that of normal mice in the obese / type 2 diabetes model (FIG. 7).
  • mice Six-week-old db / db mice were used in each experimental group, and the change in body weight was measured twice a week. The dietary intake was measured every three days, and the average daily dietary intake of each experimental group (7) was observed. The results are shown in FIGS. 8 and 9.
  • the soybean powder (ABSE) and boiled soybean (B-ABSE) groups significantly decreased blood glucose and triglyceride levels (p ⁇ 0.01, p ⁇ 0.001) compared to the non-administered group.
  • the soybean meal (ABSE) group and boiled soybean (B-ABSE) group showed higher dietary intake, no weight change, and no gross abnormalities were observed.
  • the group treated with soybean powder (ABSE) showed hypoglycemic effect to alleviate fasting hyperglycemia after fasting.
  • Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals of each group were orally administered with the soybean extract of the present invention at a dose of 100 mg / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to visually observe abnormalities in organs and thoracic organs.
  • the extract of the present invention did not show a change in toxicity even in rats up to 100 mg / kg, respectively, and the minimum lethal dose (LD 50 ) was determined to be a safe substance of 100 mg / kg or more.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional method for preparing tablets.
  • the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
  • the amount of the above ingredient is prepared per ampoule (2 ml).
  • each component is added to the purified water to dissolve it, and lemon flavor is added, the above components are mixed, and then, purified water is added to adjust the total amount to 100 ml, and then sterilized by filling into a brown bottle. do.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir et traiter le diabète qui comprend une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci qui possède un effet de réduction de la glycémie. La poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci de la présente invention peut être avantageusement utilisé dans des compositions pharmaceutiques et des aliments fonctionnels et naturels pour prévenir et traiter le diabète par suppression et régulation des augmentations soudaines de la glycémie.
PCT/KR2012/000797 2011-02-01 2012-02-01 Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci WO2012105816A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020137017487A KR101910898B1 (ko) 2011-02-01 2012-02-01 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨 합병증 예방 및 치료를 위한 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0010144 2011-02-01
KR1020110010144A KR20120089045A (ko) 2011-02-01 2011-02-01 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물

Publications (2)

Publication Number Publication Date
WO2012105816A2 true WO2012105816A2 (fr) 2012-08-09
WO2012105816A3 WO2012105816A3 (fr) 2012-12-13

Family

ID=46603216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000797 WO2012105816A2 (fr) 2011-02-01 2012-02-01 Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci

Country Status (2)

Country Link
KR (2) KR20120089045A (fr)
WO (1) WO2012105816A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961496A (zh) * 2012-12-02 2013-03-13 张娜 一种治疗经崩的中药组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101688090B1 (ko) 2016-01-15 2016-12-21 강원대학교산학협력단 돼지감자 추출물, 미강 추출물, 오미자 추출물, 여주 추출물을 함유하는 항당뇨 조성물
CN109090402A (zh) * 2018-06-28 2018-12-28 广西秀美壮乡能源环保有限公司 一种含有荔枝皮提取物的保健饮料及其加工方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089451A (ja) * 2004-09-24 2006-04-06 Koji Haraguchi 血糖値及び肥満のコントロール飲食用組成物
KR20100127728A (ko) * 2009-05-26 2010-12-06 (주)아모레퍼시픽 콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060107183A (ko) * 2005-04-08 2006-10-13 영농조합법인 영산식품 쥐눈이콩 및 쥐눈이식초콩 분말 또는 추출물을 포함하는당뇨병 예방 및 치료를 위한 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089451A (ja) * 2004-09-24 2006-04-06 Koji Haraguchi 血糖値及び肥満のコントロール飲食用組成物
KR20100127728A (ko) * 2009-05-26 2010-12-06 (주)아모레퍼시픽 콩 추출물을 함유하는 혈액 순환 개선 및 혈관 건강 증진용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961496A (zh) * 2012-12-02 2013-03-13 张娜 一种治疗经崩的中药组合物

Also Published As

Publication number Publication date
KR20140032961A (ko) 2014-03-17
KR20120089045A (ko) 2012-08-09
KR101910898B1 (ko) 2018-10-24
WO2012105816A3 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012033378A2 (fr) Composition comprenant un extrait de cudrania tricuspidata et de coix lachryma-jobi ayant une activité anti-obésité et un effet d'abaissement du taux de sucre dans le sang, et son utilisation
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2015030293A1 (fr) Composition contenant un extrait composite de raisin et de schisandra chinensis pour la prévention ou le traitement de maladies associées au syndrome métabolique
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
KR101976941B1 (ko) 토종 보리수 추출물을 포함하는 당뇨병 예방 및 치료용 조성물
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2021091164A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou l'allergie comprenant un extrait de rose comme ingrédient actif
WO2023106777A1 (fr) Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci
WO2013069934A1 (fr) Composition pour traiter et prévenir l'obésité, contenant de l'extrait d'agropyre comme principe actif
WO2023003204A1 (fr) Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
WO2022186414A1 (fr) Composition anti-inflammatoire comprenant des extraits d'epimendium koreanum nakai, de polygala tenuifolia wild, et de polyporus umbellatus fries ou un mélange de ces derniers en tant que principe actif
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
KR20120115471A (ko) 돌콩의 열처리 분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물
KR100543405B1 (ko) 산마늘 추출물을 유효성분으로 함유하는 당뇨성 질환의예방 및 치료용 조성물
KR20160059152A (ko) 엉겅퀴 잎 추출물을 유효성분으로 함유하는 항비만 조성물
KR100846521B1 (ko) 복합생약추출물(ｏｃａ－ⅰ) 또는 이의분말(ｏｃａ－ⅱ)을 함유하는 당뇨병 예방 및 치료용조성물
WO2021133091A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de la stéatohépatite non alcoolique, contenant un extrait d'aster koraiensis nakai
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2013022178A1 (fr) Composition pour prévention et traitement de l'obésité contenant un principe actif sous la forme d'un extrait de préparation végétale mélangée à base de lonicera japonica et d'aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation
WO2021246703A1 (fr) Composition anti-obésité

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741590

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 20137017487

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12741590

Country of ref document: EP

Kind code of ref document: A2